{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:49:56Z","timestamp":1791348596763,"version":"4.3.1"},"reference-count":12,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.xphs.2026.104485","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:54:52Z","timestamp":1787921692000},"page":"104485","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Deriving clearance and bioavailability from oral clinical PK studies with information on fraction absorbed, including radiolabeled mass-balance studies"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7121-4394","authenticated-orcid":false,"given":"Felix","family":"Huth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8404-6107","authenticated-orcid":false,"given":"Rowan","family":"Stringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Berghausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Glaenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander David","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grit","family":"Laue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Wellbourne-Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7503-9776","authenticated-orcid":false,"given":"Ruben","family":"de Kanter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.xphs.2026.104485_bib0002","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/psp4.12466","article-title":"The importance of the Human mass balance study in regulatory submissions","volume":"8","author":"Coppola","year":"2019","journal-title":"CPT Pharmacometr Syst Pharmacol Am Soc Clin Pharmacol Therap"},{"key":"10.1016\/j.xphs.2026.104485_bib0003","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.70257","article-title":"Advances in human mass balance studies: an IQ Consortium perspective on current practices and emerging trends","author":"Boer","year":"2026","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.xphs.2026.104485_bib0004","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40262-019-00790-0","article-title":"Requirements to establishing confidence in physiologically based pharmacokinetic (PBPK) models and overcoming some of the challenges to meeting them","volume":"58","author":"Peters","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.xphs.2026.104485_bib0005","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/00498254.2019.1594449","article-title":"Disposition of asciminib, a potent BCR-ABL1 tyrosine kinase inhibitor, in healthy male subjects","volume":"50","author":"Tran","year":"2020","journal-title":"Xenobiotica"},{"key":"10.1016\/j.xphs.2026.104485_bib0006","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejps.2016.02.022","article-title":"New IVIVE method for the prediction of total human clearance and relative elimination pathway contributions from in vitro hepatocyte and microsome data","volume":"86","author":"Riede","year":"2016","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2026.104485_bib0007","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1021\/jm901371v","article-title":"Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination","volume":"53","author":"Varma","year":"2010","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.xphs.2026.104485_bib0008","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1021\/ci700018y","article-title":"New and original pKa prediction method using grid molecular interaction fields","volume":"47","author":"Milletti","year":"2007","journal-title":"J Chem Inf Model"},{"issue":"6","key":"10.1016\/j.xphs.2026.104485_bib0009","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1016\/j.xphs.2021.01.029","article-title":"Predicting oral absorption for compounds outside the rule of five property space","volume":"110","author":"Huth","year":"2021","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2026.104485_bib0010","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-49979-3","article-title":"Application of machine learning models for property prediction to targeted protein degraders","volume":"15","author":"Peteani","year":"2024","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.xphs.2026.104485_bib0011","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40262-020-00891-1","article-title":"Chloroquine for SARS-CoV-2: implications of its unique pharmacokinetic and safety properties","volume":"59","author":"Smit","year":"2020","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.xphs.2026.104485_bib0012","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40262-022-01204-4","article-title":"Can mechanistic static models for drug-drug interactions support regulatory filing for study waivers and label recommendations?","volume":"62","author":"Gomez-Mantilla","year":"2023","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.xphs.2026.104485_bib0013","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1208\/s12248-017-0099-z","article-title":"Incorporation of the time-varying postprandial increase in splanchnic blood flow into a PBPK model to predict the effect of food on the pharmacokinetics of orally administered high-extraction drugs","volume":"19","author":"Rose","year":"2017","journal-title":"AAPS J"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926003357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926003357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:52:17Z","timestamp":1791345137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926003357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":12,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0022354926003357"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104485","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deriving clearance and bioavailability from oral clinical PK studies with information on fraction absorbed, including radiolabeled mass-balance studies","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104485","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Pharmacists Association\u00ae.","name":"copyright","label":"Copyright"}],"article-number":"104485"}}